顕微鏡

MiCAN Technologies

providing high precision artificial blood cells using hIPSc technologies

Details

MiCAN%20logo_edited.jpg

OVERVIEW

A world leading company based in Kyoto and Kobe, the heart of the sciences and technologies for regenerative medicine, now provide iPS derived high functional cell products to the global market. 

Optimised artificial blood cells from iPSC
NEW - COVID-19 optimised product (cMylc)​
Welcome to collaborative research projects
Made in Kyoto and available to the global market

KEY TECHNOLOGIES

MiCAN developed and optimised our unique methodologies to obtain reproduceable iPSC derived myeloid (immature dendritic cells) with cryopreserved format convenient for the scientists internationally.

MiCAN diff scheme.png

Optimised artificial immature blood cells from iPSC

  1. Unique and patented differentiation methods​

  2. Special immortalizing technology

  3. Cryopreservation for the global supply

  4. Supplied as ready-to-use format

Mylc

MiCAN's core technology to prepare reproduceable immature dendritic cells derived from stem cells including human iPSC. Mylc provides high-sensitivity for TLR ligands.

Key applications

Infectious disease

DENV (dengue) research

(infection, ADE detection, cell reaction)

Immune, allergy, inflammation fields

Safety test for

endotoxin (LPS assay)

skin hypersensitivity

Immune activity assay

Learn more

cMylc

Exclusively optimised Mylc cells suitable for COVID-19 (SARS-CoV-2 virus) research for vaccine and drug discovery.

Key applications

Infectious disease

SARS-CoV-2 research

(infection, ADE detection, cell reaction)

Immune, allergy, inflammation fields

Cytokine analysis introduced by COVID-19 virus infection

APPLICATIONS

LOGISTICS

飛行機

Now available for the global market with optimising cryopreservation formatting and managing the global supply chain.